Hematological Associations in Amyloidosis

Jacques Kaufman; Roberto J.P. Magalhães; Morie A. Gertz

doi:10.1007/978-3-031-17759-0_12

Hematological Associations in Amyloidosis

Jacques Kaufman, Roberto J.P. Magalhães, Morie A. Gertz

Hematology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with underlying plasma cell dyscrasia. The clinical symptoms at presentation included congestive heart failure, nephrotic syndrome with or without renal dysfunction, hepatomegaly, and autonomic or sensory neuropathy. Recent diagnostic and prognostic advances include the serum free light-chain assay, cardiac magnetic resonance imaging, and cintilography, associated with serologic cardiac biomarkers and NT-proBNP. This review outlines approaches to the epidemiology, diagnosis, and assessment of disease severity of AL amyloidosis.

Original language	English (US)
Title of host publication	Amyloidosis and Fabry Disease
Subtitle of host publication	a Clinical Guide
Publisher	Springer International Publishing
Pages	119-128
Number of pages	10
ISBN (Electronic)	9783031177590
ISBN (Print)	9783031177583
DOIs	https://doi.org/10.1007/978-3-031-17759-0_12
State	Published - Jan 1 2023

Keywords

(AL) amyloidosis
Amyloid fibrils
Monoclonal gammopathies
Monoclonal light chains
Restrictive cardiomyopathy and nephrotic syndrome

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-031-17759-0_12

Cite this

@inbook{acde984c63f44b219cd3f523f0355e01,

title = "Hematological Associations in Amyloidosis",

abstract = "Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with underlying plasma cell dyscrasia. The clinical symptoms at presentation included congestive heart failure, nephrotic syndrome with or without renal dysfunction, hepatomegaly, and autonomic or sensory neuropathy. Recent diagnostic and prognostic advances include the serum free light-chain assay, cardiac magnetic resonance imaging, and cintilography, associated with serologic cardiac biomarkers and NT-proBNP. This review outlines approaches to the epidemiology, diagnosis, and assessment of disease severity of AL amyloidosis.",

keywords = "(AL) amyloidosis, Amyloid fibrils, Monoclonal gammopathies, Monoclonal light chains, Restrictive cardiomyopathy and nephrotic syndrome",

author = "Jacques Kaufman and Magalh{\~a}es, {Roberto J.P.} and Gertz, {Morie A.}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1007/978-3-031-17759-0_12",

language = "English (US)",

isbn = "9783031177583",

pages = "119--128",

booktitle = "Amyloidosis and Fabry Disease",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Hematological Associations in Amyloidosis

AU - Kaufman, Jacques

AU - Magalhães, Roberto J.P.

AU - Gertz, Morie A.

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with underlying plasma cell dyscrasia. The clinical symptoms at presentation included congestive heart failure, nephrotic syndrome with or without renal dysfunction, hepatomegaly, and autonomic or sensory neuropathy. Recent diagnostic and prognostic advances include the serum free light-chain assay, cardiac magnetic resonance imaging, and cintilography, associated with serologic cardiac biomarkers and NT-proBNP. This review outlines approaches to the epidemiology, diagnosis, and assessment of disease severity of AL amyloidosis.

AB - Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with underlying plasma cell dyscrasia. The clinical symptoms at presentation included congestive heart failure, nephrotic syndrome with or without renal dysfunction, hepatomegaly, and autonomic or sensory neuropathy. Recent diagnostic and prognostic advances include the serum free light-chain assay, cardiac magnetic resonance imaging, and cintilography, associated with serologic cardiac biomarkers and NT-proBNP. This review outlines approaches to the epidemiology, diagnosis, and assessment of disease severity of AL amyloidosis.

KW - (AL) amyloidosis

KW - Amyloid fibrils

KW - Monoclonal gammopathies

KW - Monoclonal light chains

KW - Restrictive cardiomyopathy and nephrotic syndrome

UR - http://www.scopus.com/inward/record.url?scp=85171007810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85171007810&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-17759-0_12

DO - 10.1007/978-3-031-17759-0_12

M3 - Chapter

AN - SCOPUS:85171007810

SN - 9783031177583

SP - 119

EP - 128

BT - Amyloidosis and Fabry Disease

PB - Springer International Publishing

ER -

Hematological Associations in Amyloidosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this